Global Non-muscle Invasive Bladder Cancer Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Global Non-muscle Invasive Bladder Cancer Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Page: 121

Published Date: 25 Jun 2022

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

  • sp_icon1 sp_icon1_b Description
  • sp_icon2 sp_icon2_b Table of Contents
  • sp_icon3 sp_icon3_b Table of Figures
  • sp_icon4 sp_icon4_b Research Methodology
  • sp_icon1 sp_icon1_b Companies Mentioned
  • sp_icon1 sp_icon1_b Product Tags
btl

Description

The Non-muscle Invasive Bladder Cancer Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Non-muscle Invasive Bladder Cancer Therapeutics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital accounting for % of the Non-muscle Invasive Bladder Cancer Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Intravesical Chemotherapy segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Non-muscle Invasive Bladder Cancer Therapeutics include F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., and GlaxoSmithKline plc., etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation
Non-muscle Invasive Bladder Cancer Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Intravesical Chemotherapy
Intravesical Immunotherapy

Market segment by Application, can be divided into
Hospital
Ambulatory Surgery Center
Others

Market segment by players, this report covers
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
AstraZeneca
Pfizer Inc.
GlaxoSmithKline plc.
Sanofi S.A.
Novartis AG
Eli Lilly and Company
Merck & Co.
Viventia Bio Inc.
Celgene Corporation
Spectrum Pharmaceuticals, Inc.
Herantis Pharma Plc.
Taris Biomedical LLC
Prometic Life Sciences Inc.
Telormediz S.A.
Heat Biologics
Altor BioScience
Ferring B.V.
Cold Genesys Inc.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Non-muscle Invasive Bladder Cancer Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Non-muscle Invasive Bladder Cancer Therapeutics, with revenue, gross margin and global market share of Non-muscle Invasive Bladder Cancer Therapeutics from 2019 to 2022.
Chapter 3, the Non-muscle Invasive Bladder Cancer Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Non-muscle Invasive Bladder Cancer Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Non-muscle Invasive Bladder Cancer Therapeutics research findings and conclusion, appendix and data source.
btl

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Non-muscle Invasive Bladder Cancer Therapeutics
1.2 Classification of Non-muscle Invasive Bladder Cancer Therapeutics by Type
1.2.1 Overview: Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Type in 2021
1.2.3 Intravesical Chemotherapy
1.2.4 Intravesical Immunotherapy
1.3 Global Non-muscle Invasive Bladder Cancer Therapeutics Market by Application
1.3.1 Overview: Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Ambulatory Surgery Center
1.3.4 Others
1.4 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size & Forecast
1.5 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast by Region
1.5.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region, (2017-2022)
1.5.3 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Prospect (2017-2028)
1.5.4 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Prospect (2017-2028)
1.5.6 South America Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers
1.6.2 Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints
1.6.3 Non-muscle Invasive Bladder Cancer Therapeutics Trends Analysis

2 Company Profiles
2.1 F. Hoffmann-La Roche Ltd.
2.1.1 F. Hoffmann-La Roche Ltd. Details
2.1.2 F. Hoffmann-La Roche Ltd. Major Business
2.1.3 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.1.4 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.2 Bristol-Myers Squibb Company
2.2.1 Bristol-Myers Squibb Company Details
2.2.2 Bristol-Myers Squibb Company Major Business
2.2.3 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.2.4 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.3.4 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 AstraZeneca Recent Developments and Future Plans
2.4 Pfizer Inc.
2.4.1 Pfizer Inc. Details
2.4.2 Pfizer Inc. Major Business
2.4.3 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.4.4 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Pfizer Inc. Recent Developments and Future Plans
2.5 GlaxoSmithKline plc.
2.5.1 GlaxoSmithKline plc. Details
2.5.2 GlaxoSmithKline plc. Major Business
2.5.3 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.5.4 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 GlaxoSmithKline plc. Recent Developments and Future Plans
2.6 Sanofi S.A.
2.6.1 Sanofi S.A. Details
2.6.2 Sanofi S.A. Major Business
2.6.3 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.6.4 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Sanofi S.A. Recent Developments and Future Plans
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business
2.7.3 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.7.4 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Novartis AG Recent Developments and Future Plans
2.8 Eli Lilly and Company
2.8.1 Eli Lilly and Company Details
2.8.2 Eli Lilly and Company Major Business
2.8.3 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.8.4 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Eli Lilly and Company Recent Developments and Future Plans
2.9 Merck & Co.
2.9.1 Merck & Co. Details
2.9.2 Merck & Co. Major Business
2.9.3 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.9.4 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Merck & Co. Recent Developments and Future Plans
2.10 Viventia Bio Inc.
2.10.1 Viventia Bio Inc. Details
2.10.2 Viventia Bio Inc. Major Business
2.10.3 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.10.4 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Viventia Bio Inc. Recent Developments and Future Plans
2.11 Celgene Corporation
2.11.1 Celgene Corporation Details
2.11.2 Celgene Corporation Major Business
2.11.3 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.11.4 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Celgene Corporation Recent Developments and Future Plans
2.12 Spectrum Pharmaceuticals, Inc.
2.12.1 Spectrum Pharmaceuticals, Inc. Details
2.12.2 Spectrum Pharmaceuticals, Inc. Major Business
2.12.3 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.12.4 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Spectrum Pharmaceuticals, Inc. Recent Developments and Future Plans
2.13 Herantis Pharma Plc.
2.13.1 Herantis Pharma Plc. Details
2.13.2 Herantis Pharma Plc. Major Business
2.13.3 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.13.4 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Herantis Pharma Plc. Recent Developments and Future Plans
2.14 Taris Biomedical LLC
2.14.1 Taris Biomedical LLC Details
2.14.2 Taris Biomedical LLC Major Business
2.14.3 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.14.4 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Taris Biomedical LLC Recent Developments and Future Plans
2.15 Prometic Life Sciences Inc.
2.15.1 Prometic Life Sciences Inc. Details
2.15.2 Prometic Life Sciences Inc. Major Business
2.15.3 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.15.4 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Prometic Life Sciences Inc. Recent Developments and Future Plans
2.16 Telormediz S.A.
2.16.1 Telormediz S.A. Details
2.16.2 Telormediz S.A. Major Business
2.16.3 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.16.4 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 Telormediz S.A. Recent Developments and Future Plans
2.17 Heat Biologics
2.17.1 Heat Biologics Details
2.17.2 Heat Biologics Major Business
2.17.3 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.17.4 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Heat Biologics Recent Developments and Future Plans
2.18 Altor BioScience
2.18.1 Altor BioScience Details
2.18.2 Altor BioScience Major Business
2.18.3 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.18.4 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 Altor BioScience Recent Developments and Future Plans
2.19 Ferring B.V.
2.19.1 Ferring B.V. Details
2.19.2 Ferring B.V. Major Business
2.19.3 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.19.4 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 Ferring B.V. Recent Developments and Future Plans
2.20 Cold Genesys Inc.
2.20.1 Cold Genesys Inc. Details
2.20.2 Cold Genesys Inc. Major Business
2.20.3 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.20.4 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 Cold Genesys Inc. Recent Developments and Future Plans

3 Market Competition, by Players
3.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Non-muscle Invasive Bladder Cancer Therapeutics Players Market Share in 2021
3.2.2 Top 10 Non-muscle Invasive Bladder Cancer Therapeutics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Non-muscle Invasive Bladder Cancer Therapeutics Players Head Office, Products and Services Provided
3.4 Non-muscle Invasive Bladder Cancer Therapeutics Mergers & Acquisitions
3.5 Non-muscle Invasive Bladder Cancer Therapeutics New Entrants and Expansion Plans

4 Market Size Segment by Type
4.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Market Share by Type (2017-2022)
4.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast by Type (2023-2028)

5 Market Size Segment by Application
5.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Application (2017-2022)
5.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application
6.1 North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2028)
6.2 North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2028)
6.3 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country
6.3.1 North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2028)
6.3.2 United States Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
6.3.3 Canada Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
6.3.4 Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application
7.1 Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2028)
7.2 Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2028)
7.3 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country
7.3.1 Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2028)
7.3.2 Germany Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
7.3.3 France Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
7.3.5 Russia Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
7.3.6 Italy Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2028)
8.2 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2028)
8.3 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region
8.3.1 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Region (2017-2028)
8.3.2 China Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.3 Japan Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.4 South Korea Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.5 India Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.7 Australia Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application
9.1 South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2028)
9.2 South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2028)
9.3 South America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country
9.3.1 South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2028)
9.3.2 Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
9.3.3 Argentina Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2028)
10.2 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2028)
10.3 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country
10.3.1 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2028)
10.3.2 Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
10.3.4 UAE Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Non-muscle Invasive Bladder Cancer Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Region (2023-2028)
Table 6. F. Hoffmann-La Roche Ltd. Corporate Information, Head Office, and Major Competitors
Table 7. F. Hoffmann-La Roche Ltd. Major Business
Table 8. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 9. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Company Major Business
Table 12. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 13. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 15. AstraZeneca Major Business
Table 16. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 17. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Pfizer Inc. Corporate Information, Head Office, and Major Competitors
Table 19. Pfizer Inc. Major Business
Table 20. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 21. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. GlaxoSmithKline plc. Corporate Information, Head Office, and Major Competitors
Table 23. GlaxoSmithKline plc. Major Business
Table 24. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 25. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Sanofi S.A. Corporate Information, Head Office, and Major Competitors
Table 27. Sanofi S.A. Major Business
Table 28. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 29. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 31. Novartis AG Major Business
Table 32. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 33. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 35. Eli Lilly and Company Major Business
Table 36. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 37. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Merck & Co. Corporate Information, Head Office, and Major Competitors
Table 39. Merck & Co. Major Business
Table 40. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 41. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Viventia Bio Inc. Corporate Information, Head Office, and Major Competitors
Table 43. Viventia Bio Inc. Major Business
Table 44. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 45. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Celgene Corporation Corporate Information, Head Office, and Major Competitors
Table 47. Celgene Corporation Major Business
Table 48. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 49. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Spectrum Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 51. Spectrum Pharmaceuticals, Inc. Major Business
Table 52. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 53. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Herantis Pharma Plc. Corporate Information, Head Office, and Major Competitors
Table 55. Herantis Pharma Plc. Major Business
Table 56. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 57. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Taris Biomedical LLC Corporate Information, Head Office, and Major Competitors
Table 59. Taris Biomedical LLC Major Business
Table 60. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 61. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Prometic Life Sciences Inc. Corporate Information, Head Office, and Major Competitors
Table 63. Prometic Life Sciences Inc. Major Business
Table 64. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 65. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Telormediz S.A. Corporate Information, Head Office, and Major Competitors
Table 67. Telormediz S.A. Major Business
Table 68. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 69. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Heat Biologics Corporate Information, Head Office, and Major Competitors
Table 71. Heat Biologics Major Business
Table 72. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 73. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Altor BioScience Corporate Information, Head Office, and Major Competitors
Table 75. Altor BioScience Major Business
Table 76. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 77. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Ferring B.V. Corporate Information, Head Office, and Major Competitors
Table 79. Ferring B.V. Major Business
Table 80. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 81. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Cold Genesys Inc. Corporate Information, Head Office, and Major Competitors
Table 83. Cold Genesys Inc. Major Business
Table 84. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 85. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 87. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 88. Breakdown of Non-muscle Invasive Bladder Cancer Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 89. Non-muscle Invasive Bladder Cancer Therapeutics Players Head Office, Products and Services Provided
Table 90. Non-muscle Invasive Bladder Cancer Therapeutics Mergers & Acquisitions in the Past Five Years
Table 91. Non-muscle Invasive Bladder Cancer Therapeutics New Entrants and Expansion Plans
Table 92. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) by Type (2017-2022)
Table 93. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Type (2017-2022)
Table 94. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Forecast by Type (2023-2028)
Table 95. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2022)
Table 96. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Forecast by Application (2023-2028)
Table 97. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 98. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 99. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 100. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 101. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 102. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 103. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 104. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 105. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 106. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 107. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 108. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 109. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 110. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 111. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 112. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 113. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 114. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 115. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 116. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 117. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 118. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 119. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 120. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 121. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 122. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 123. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 124. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 125. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 126. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Non-muscle Invasive Bladder Cancer Therapeutics Picture
Figure 2. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Type in 2021
Figure 3. Intravesical Chemotherapy
Figure 4. Intravesical Immunotherapy
Figure 5. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Application in 2021
Figure 6. Hospital Picture
Figure 7. Ambulatory Surgery Center Picture
Figure 8. Others Picture
Figure 9. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 10. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Region (2017-2028)
Figure 12. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Region in 2021
Figure 13. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Middle East and Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers
Figure 19. Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints
Figure 20. Non-muscle Invasive Bladder Cancer Therapeutics Market Trends
Figure 21. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
Figure 22. Bristol-Myers Squibb Company Recent Developments and Future Plans
Figure 23. AstraZeneca Recent Developments and Future Plans
Figure 24. Pfizer Inc. Recent Developments and Future Plans
Figure 25. GlaxoSmithKline plc. Recent Developments and Future Plans
Figure 26. Sanofi S.A. Recent Developments and Future Plans
Figure 27. Novartis AG Recent Developments and Future Plans
Figure 28. Eli Lilly and Company Recent Developments and Future Plans
Figure 29. Merck & Co. Recent Developments and Future Plans
Figure 30. Viventia Bio Inc. Recent Developments and Future Plans
Figure 31. Celgene Corporation Recent Developments and Future Plans
Figure 32. Spectrum Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 33. Herantis Pharma Plc. Recent Developments and Future Plans
Figure 34. Taris Biomedical LLC Recent Developments and Future Plans
Figure 35. Prometic Life Sciences Inc. Recent Developments and Future Plans
Figure 36. Telormediz S.A. Recent Developments and Future Plans
Figure 37. Heat Biologics Recent Developments and Future Plans
Figure 38. Altor BioScience Recent Developments and Future Plans
Figure 39. Ferring B.V. Recent Developments and Future Plans
Figure 40. Cold Genesys Inc. Recent Developments and Future Plans
Figure 41. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Players in 2021
Figure 42. Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 43. Global Top 3 Players Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share in 2021
Figure 44. Global Top 10 Players Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share in 2021
Figure 45. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 46. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Type in 2021
Figure 47. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share Forecast by Type (2023-2028)
Figure 48. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Application in 2021
Figure 49. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share Forecast by Application (2023-2028)
Figure 50. North America Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 51. North America Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 52. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Country (2017-2028)
Figure 53. United States Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Canada Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Europe Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 57. Europe Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 58. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Country (2017-2028)
Figure 59. Germany Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. France Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. United Kingdom Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Russia Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Italy Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 65. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 66. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Region (2017-2028)
Figure 67. China Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Japan Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. India Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Australia Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. South America Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 74. South America Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 75. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Country (2017-2028)
Figure 76. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Argentina Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Middle East and Africa Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Country (2017-2028)
Figure 81. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 82. Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 83. UAE Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 84. Methodology
Figure 85. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
AstraZeneca
Pfizer Inc.
GlaxoSmithKline plc.
Sanofi S.A.
Novartis AG
Eli Lilly and Company
Merck & Co.
Viventia Bio Inc.
Celgene Corporation
Spectrum Pharmaceuticals, Inc.
Herantis Pharma Plc.
Taris Biomedical LLC
Prometic Life Sciences Inc.
Telormediz S.A.
Heat Biologics
Altor BioScience
Ferring B.V.
Cold Genesys Inc.
shop_t

Purchase Options

jiaGou

Add To Cart

jiaGou

Buy Now

masterCard
visa
jcb
americanExpress
shop_b
Global Non-muscle Invasive Bladder Cancer Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Global Non-muscle Invasive Bladder Cancer Therapeutics Market 2022 by Company, Regions, Type and Application, Forecast to 2028

Page: 121

Published Date: 25 Jun 2022

Category: Medical Care

PDF Download

Get FREE Sample

Customize Request

Description

arrow-d3
btl

Description

The Non-muscle Invasive Bladder Cancer Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Non-muscle Invasive Bladder Cancer Therapeutics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Hospital accounting for % of the Non-muscle Invasive Bladder Cancer Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Intravesical Chemotherapy segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Non-muscle Invasive Bladder Cancer Therapeutics include F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca, Pfizer Inc., and GlaxoSmithKline plc., etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation
Non-muscle Invasive Bladder Cancer Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Intravesical Chemotherapy
Intravesical Immunotherapy

Market segment by Application, can be divided into
Hospital
Ambulatory Surgery Center
Others

Market segment by players, this report covers
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
AstraZeneca
Pfizer Inc.
GlaxoSmithKline plc.
Sanofi S.A.
Novartis AG
Eli Lilly and Company
Merck & Co.
Viventia Bio Inc.
Celgene Corporation
Spectrum Pharmaceuticals, Inc.
Herantis Pharma Plc.
Taris Biomedical LLC
Prometic Life Sciences Inc.
Telormediz S.A.
Heat Biologics
Altor BioScience
Ferring B.V.
Cold Genesys Inc.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Non-muscle Invasive Bladder Cancer Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Non-muscle Invasive Bladder Cancer Therapeutics, with revenue, gross margin and global market share of Non-muscle Invasive Bladder Cancer Therapeutics from 2019 to 2022.
Chapter 3, the Non-muscle Invasive Bladder Cancer Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Non-muscle Invasive Bladder Cancer Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Non-muscle Invasive Bladder Cancer Therapeutics research findings and conclusion, appendix and data source.
btl

Table of Contents

1 Market Overview
1.1 Product Overview and Scope of Non-muscle Invasive Bladder Cancer Therapeutics
1.2 Classification of Non-muscle Invasive Bladder Cancer Therapeutics by Type
1.2.1 Overview: Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Type in 2021
1.2.3 Intravesical Chemotherapy
1.2.4 Intravesical Immunotherapy
1.3 Global Non-muscle Invasive Bladder Cancer Therapeutics Market by Application
1.3.1 Overview: Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Ambulatory Surgery Center
1.3.4 Others
1.4 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size & Forecast
1.5 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast by Region
1.5.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region, (2017-2022)
1.5.3 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Prospect (2017-2028)
1.5.4 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Prospect (2017-2028)
1.5.6 South America Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers
1.6.2 Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints
1.6.3 Non-muscle Invasive Bladder Cancer Therapeutics Trends Analysis

2 Company Profiles
2.1 F. Hoffmann-La Roche Ltd.
2.1.1 F. Hoffmann-La Roche Ltd. Details
2.1.2 F. Hoffmann-La Roche Ltd. Major Business
2.1.3 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.1.4 F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
2.2 Bristol-Myers Squibb Company
2.2.1 Bristol-Myers Squibb Company Details
2.2.2 Bristol-Myers Squibb Company Major Business
2.2.3 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.2.4 Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.3 AstraZeneca
2.3.1 AstraZeneca Details
2.3.2 AstraZeneca Major Business
2.3.3 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.3.4 AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 AstraZeneca Recent Developments and Future Plans
2.4 Pfizer Inc.
2.4.1 Pfizer Inc. Details
2.4.2 Pfizer Inc. Major Business
2.4.3 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.4.4 Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Pfizer Inc. Recent Developments and Future Plans
2.5 GlaxoSmithKline plc.
2.5.1 GlaxoSmithKline plc. Details
2.5.2 GlaxoSmithKline plc. Major Business
2.5.3 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.5.4 GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 GlaxoSmithKline plc. Recent Developments and Future Plans
2.6 Sanofi S.A.
2.6.1 Sanofi S.A. Details
2.6.2 Sanofi S.A. Major Business
2.6.3 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.6.4 Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Sanofi S.A. Recent Developments and Future Plans
2.7 Novartis AG
2.7.1 Novartis AG Details
2.7.2 Novartis AG Major Business
2.7.3 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.7.4 Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Novartis AG Recent Developments and Future Plans
2.8 Eli Lilly and Company
2.8.1 Eli Lilly and Company Details
2.8.2 Eli Lilly and Company Major Business
2.8.3 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.8.4 Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Eli Lilly and Company Recent Developments and Future Plans
2.9 Merck & Co.
2.9.1 Merck & Co. Details
2.9.2 Merck & Co. Major Business
2.9.3 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.9.4 Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Merck & Co. Recent Developments and Future Plans
2.10 Viventia Bio Inc.
2.10.1 Viventia Bio Inc. Details
2.10.2 Viventia Bio Inc. Major Business
2.10.3 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.10.4 Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Viventia Bio Inc. Recent Developments and Future Plans
2.11 Celgene Corporation
2.11.1 Celgene Corporation Details
2.11.2 Celgene Corporation Major Business
2.11.3 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.11.4 Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Celgene Corporation Recent Developments and Future Plans
2.12 Spectrum Pharmaceuticals, Inc.
2.12.1 Spectrum Pharmaceuticals, Inc. Details
2.12.2 Spectrum Pharmaceuticals, Inc. Major Business
2.12.3 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.12.4 Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Spectrum Pharmaceuticals, Inc. Recent Developments and Future Plans
2.13 Herantis Pharma Plc.
2.13.1 Herantis Pharma Plc. Details
2.13.2 Herantis Pharma Plc. Major Business
2.13.3 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.13.4 Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Herantis Pharma Plc. Recent Developments and Future Plans
2.14 Taris Biomedical LLC
2.14.1 Taris Biomedical LLC Details
2.14.2 Taris Biomedical LLC Major Business
2.14.3 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.14.4 Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Taris Biomedical LLC Recent Developments and Future Plans
2.15 Prometic Life Sciences Inc.
2.15.1 Prometic Life Sciences Inc. Details
2.15.2 Prometic Life Sciences Inc. Major Business
2.15.3 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.15.4 Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Prometic Life Sciences Inc. Recent Developments and Future Plans
2.16 Telormediz S.A.
2.16.1 Telormediz S.A. Details
2.16.2 Telormediz S.A. Major Business
2.16.3 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.16.4 Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 Telormediz S.A. Recent Developments and Future Plans
2.17 Heat Biologics
2.17.1 Heat Biologics Details
2.17.2 Heat Biologics Major Business
2.17.3 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.17.4 Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Heat Biologics Recent Developments and Future Plans
2.18 Altor BioScience
2.18.1 Altor BioScience Details
2.18.2 Altor BioScience Major Business
2.18.3 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.18.4 Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 Altor BioScience Recent Developments and Future Plans
2.19 Ferring B.V.
2.19.1 Ferring B.V. Details
2.19.2 Ferring B.V. Major Business
2.19.3 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.19.4 Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 Ferring B.V. Recent Developments and Future Plans
2.20 Cold Genesys Inc.
2.20.1 Cold Genesys Inc. Details
2.20.2 Cold Genesys Inc. Major Business
2.20.3 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
2.20.4 Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 Cold Genesys Inc. Recent Developments and Future Plans

3 Market Competition, by Players
3.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Non-muscle Invasive Bladder Cancer Therapeutics Players Market Share in 2021
3.2.2 Top 10 Non-muscle Invasive Bladder Cancer Therapeutics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Non-muscle Invasive Bladder Cancer Therapeutics Players Head Office, Products and Services Provided
3.4 Non-muscle Invasive Bladder Cancer Therapeutics Mergers & Acquisitions
3.5 Non-muscle Invasive Bladder Cancer Therapeutics New Entrants and Expansion Plans

4 Market Size Segment by Type
4.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Market Share by Type (2017-2022)
4.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast by Type (2023-2028)

5 Market Size Segment by Application
5.1 Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Application (2017-2022)
5.2 Global Non-muscle Invasive Bladder Cancer Therapeutics Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application
6.1 North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2028)
6.2 North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2028)
6.3 North America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country
6.3.1 North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2028)
6.3.2 United States Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
6.3.3 Canada Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
6.3.4 Mexico Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application
7.1 Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2028)
7.2 Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2028)
7.3 Europe Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country
7.3.1 Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2028)
7.3.2 Germany Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
7.3.3 France Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
7.3.5 Russia Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
7.3.6 Italy Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2028)
8.2 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2028)
8.3 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Region
8.3.1 Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Region (2017-2028)
8.3.2 China Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.3 Japan Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.4 South Korea Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.5 India Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
8.3.7 Australia Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application
9.1 South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2028)
9.2 South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2028)
9.3 South America Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country
9.3.1 South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2028)
9.3.2 Brazil Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
9.3.3 Argentina Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2028)
10.2 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2028)
10.3 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Market Size by Country
10.3.1 Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2028)
10.3.2 Turkey Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)
10.3.4 UAE Non-muscle Invasive Bladder Cancer Therapeutics Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
btl

Table of Figures

List of Tables
Table 1. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Non-muscle Invasive Bladder Cancer Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Region (2023-2028)
Table 6. F. Hoffmann-La Roche Ltd. Corporate Information, Head Office, and Major Competitors
Table 7. F. Hoffmann-La Roche Ltd. Major Business
Table 8. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 9. F. Hoffmann-La Roche Ltd. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Company Major Business
Table 12. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 13. Bristol-Myers Squibb Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 15. AstraZeneca Major Business
Table 16. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 17. AstraZeneca Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Pfizer Inc. Corporate Information, Head Office, and Major Competitors
Table 19. Pfizer Inc. Major Business
Table 20. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 21. Pfizer Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. GlaxoSmithKline plc. Corporate Information, Head Office, and Major Competitors
Table 23. GlaxoSmithKline plc. Major Business
Table 24. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 25. GlaxoSmithKline plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Sanofi S.A. Corporate Information, Head Office, and Major Competitors
Table 27. Sanofi S.A. Major Business
Table 28. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 29. Sanofi S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Novartis AG Corporate Information, Head Office, and Major Competitors
Table 31. Novartis AG Major Business
Table 32. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 33. Novartis AG Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Eli Lilly and Company Corporate Information, Head Office, and Major Competitors
Table 35. Eli Lilly and Company Major Business
Table 36. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 37. Eli Lilly and Company Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Merck & Co. Corporate Information, Head Office, and Major Competitors
Table 39. Merck & Co. Major Business
Table 40. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 41. Merck & Co. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Viventia Bio Inc. Corporate Information, Head Office, and Major Competitors
Table 43. Viventia Bio Inc. Major Business
Table 44. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 45. Viventia Bio Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Celgene Corporation Corporate Information, Head Office, and Major Competitors
Table 47. Celgene Corporation Major Business
Table 48. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 49. Celgene Corporation Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Spectrum Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 51. Spectrum Pharmaceuticals, Inc. Major Business
Table 52. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 53. Spectrum Pharmaceuticals, Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Herantis Pharma Plc. Corporate Information, Head Office, and Major Competitors
Table 55. Herantis Pharma Plc. Major Business
Table 56. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 57. Herantis Pharma Plc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Taris Biomedical LLC Corporate Information, Head Office, and Major Competitors
Table 59. Taris Biomedical LLC Major Business
Table 60. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 61. Taris Biomedical LLC Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Prometic Life Sciences Inc. Corporate Information, Head Office, and Major Competitors
Table 63. Prometic Life Sciences Inc. Major Business
Table 64. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 65. Prometic Life Sciences Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Telormediz S.A. Corporate Information, Head Office, and Major Competitors
Table 67. Telormediz S.A. Major Business
Table 68. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 69. Telormediz S.A. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Heat Biologics Corporate Information, Head Office, and Major Competitors
Table 71. Heat Biologics Major Business
Table 72. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 73. Heat Biologics Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. Altor BioScience Corporate Information, Head Office, and Major Competitors
Table 75. Altor BioScience Major Business
Table 76. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 77. Altor BioScience Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Ferring B.V. Corporate Information, Head Office, and Major Competitors
Table 79. Ferring B.V. Major Business
Table 80. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 81. Ferring B.V. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Cold Genesys Inc. Corporate Information, Head Office, and Major Competitors
Table 83. Cold Genesys Inc. Major Business
Table 84. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Product and Solutions
Table 85. Cold Genesys Inc. Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 87. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 88. Breakdown of Non-muscle Invasive Bladder Cancer Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 89. Non-muscle Invasive Bladder Cancer Therapeutics Players Head Office, Products and Services Provided
Table 90. Non-muscle Invasive Bladder Cancer Therapeutics Mergers & Acquisitions in the Past Five Years
Table 91. Non-muscle Invasive Bladder Cancer Therapeutics New Entrants and Expansion Plans
Table 92. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) by Type (2017-2022)
Table 93. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Type (2017-2022)
Table 94. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Forecast by Type (2023-2028)
Table 95. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2022)
Table 96. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Forecast by Application (2023-2028)
Table 97. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 98. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 99. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 100. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 101. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 102. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 103. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 104. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 105. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 106. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 107. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 108. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 109. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 110. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 111. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 112. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 113. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 114. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 115. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 116. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 117. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 118. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 119. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 120. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 121. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 122. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 123. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 124. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 125. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 126. Middle East & Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Non-muscle Invasive Bladder Cancer Therapeutics Picture
Figure 2. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Type in 2021
Figure 3. Intravesical Chemotherapy
Figure 4. Intravesical Immunotherapy
Figure 5. Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Application in 2021
Figure 6. Hospital Picture
Figure 7. Ambulatory Surgery Center Picture
Figure 8. Others Picture
Figure 9. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 10. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Region (2017-2028)
Figure 12. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Region in 2021
Figure 13. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Middle East and Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Non-muscle Invasive Bladder Cancer Therapeutics Market Drivers
Figure 19. Non-muscle Invasive Bladder Cancer Therapeutics Market Restraints
Figure 20. Non-muscle Invasive Bladder Cancer Therapeutics Market Trends
Figure 21. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
Figure 22. Bristol-Myers Squibb Company Recent Developments and Future Plans
Figure 23. AstraZeneca Recent Developments and Future Plans
Figure 24. Pfizer Inc. Recent Developments and Future Plans
Figure 25. GlaxoSmithKline plc. Recent Developments and Future Plans
Figure 26. Sanofi S.A. Recent Developments and Future Plans
Figure 27. Novartis AG Recent Developments and Future Plans
Figure 28. Eli Lilly and Company Recent Developments and Future Plans
Figure 29. Merck & Co. Recent Developments and Future Plans
Figure 30. Viventia Bio Inc. Recent Developments and Future Plans
Figure 31. Celgene Corporation Recent Developments and Future Plans
Figure 32. Spectrum Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 33. Herantis Pharma Plc. Recent Developments and Future Plans
Figure 34. Taris Biomedical LLC Recent Developments and Future Plans
Figure 35. Prometic Life Sciences Inc. Recent Developments and Future Plans
Figure 36. Telormediz S.A. Recent Developments and Future Plans
Figure 37. Heat Biologics Recent Developments and Future Plans
Figure 38. Altor BioScience Recent Developments and Future Plans
Figure 39. Ferring B.V. Recent Developments and Future Plans
Figure 40. Cold Genesys Inc. Recent Developments and Future Plans
Figure 41. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Players in 2021
Figure 42. Non-muscle Invasive Bladder Cancer Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 43. Global Top 3 Players Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share in 2021
Figure 44. Global Top 10 Players Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share in 2021
Figure 45. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 46. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Type in 2021
Figure 47. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share Forecast by Type (2023-2028)
Figure 48. Global Non-muscle Invasive Bladder Cancer Therapeutics Revenue Share by Application in 2021
Figure 49. Global Non-muscle Invasive Bladder Cancer Therapeutics Market Share Forecast by Application (2023-2028)
Figure 50. North America Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 51. North America Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 52. North America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Country (2017-2028)
Figure 53. United States Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Canada Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. Mexico Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Europe Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 57. Europe Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 58. Europe Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Country (2017-2028)
Figure 59. Germany Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. France Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. United Kingdom Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Russia Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Italy Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 65. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 66. Asia-Pacific Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Region (2017-2028)
Figure 67. China Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Japan Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. South Korea Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. India Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Southeast Asia Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Australia Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. South America Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 74. South America Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 75. South America Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Country (2017-2028)
Figure 76. Brazil Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Argentina Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Middle East and Africa Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Non-muscle Invasive Bladder Cancer Therapeutics Sales Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Non-muscle Invasive Bladder Cancer Therapeutics Revenue Market Share by Country (2017-2028)
Figure 81. Turkey Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 82. Saudi Arabia Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 83. UAE Non-muscle Invasive Bladder Cancer Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 84. Methodology
Figure 85. Research Process and Data Source
btl

Research Methodology

Client Requirements

yuan2

Review and analyze client requirements

yuan2

Discussion of all the project requirements and queries

Flexibility Check

yuan2

Project Feasibility Analysis

yuan2

Finalizing tentative research programme

yuan2

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

yuan2

Determination of key drivers, restraints, challenge, and opportunity

yuan2

Identifies market needs and trends

Market Size Estimation & Forecast

yuan2

Estimation of historical data based on secondary and primary data

yuan2

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

yuan2

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

yuan2

Consideration of geography, region-specific product/service demand for region segments

yuan2

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

tuBiao1

Data Source

yuan2

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

yuan2

Discussion of all the project requirements and queries

Validation and triangulation of secondary and primary source.

yuan2

Collection of data

yuan2

Cumulating and collating the essential qualitative and quantitative data

yuan2

Generation of report in client requested format by research analysts

yuan2

Reviews by expert analysts

yuan2

Final quality check

yuan2

Clarifying queries

yuan2

Receiving feedback

yuan2

Ensuring satisfaction

  • yuan01
    liuCheng01

    01 Identification of data

    This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.

  • yuan01
    liuCheng01

    02 Evaluation of Market Dynamic

    This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.

  • yuan01
    liuCheng01

    03 Collection of Data

    This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.

  • yuan01
    liuCheng01

    04 Collaboration of Data

    This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.

  • yuan01
    liuCheng01

    05 Verification and Analysis

    This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

btl

Companies Mentioned

F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company
AstraZeneca
Pfizer Inc.
GlaxoSmithKline plc.
Sanofi S.A.
Novartis AG
Eli Lilly and Company
Merck & Co.
Viventia Bio Inc.
Celgene Corporation
Spectrum Pharmaceuticals, Inc.
Herantis Pharma Plc.
Taris Biomedical LLC
Prometic Life Sciences Inc.
Telormediz S.A.
Heat Biologics
Altor BioScience
Ferring B.V.
Cold Genesys Inc.
jiaGou

Add To Cart

gouMai

Buy Now